$AVLV

Avantis U.S. Large Cap Value (AVLV) Adds Exxon Mobil on Oct. 22

Avantis U.S. Large Cap Value ETF (AVLV) reported $713.9M in net buying on Oct 22, with a new $569.1M stake in Exxon Mobil (XOM) as its largest purchase. The fund also added positions in WMT, NEM, LLY, and ACN, while trimming COST, CAT, CB, GS, and MET. AVLV's assets stood at $22.69B.

Original reporting
Published Oct 26, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 11:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Avantis U.S. Large Cap Value (AVLV) Adds Exxon Mobil on Oct. 22 — source image
Decision brief

The 30-second read

$AVLVBullishLow
01

Why it matters

For traders, the actionable signal is mainly relative positioning within a value ETF, not a direct fundamental catalyst for the underlying companies.

02

Market read

This is a holdings-trade disclosure that can slightly influence near-term relative sentiment, especially for XOM, but it is unlikely to drive large price moves by itself.

03

What to watch

The article does not state whether the buy is part of a systematic model rebalance, nor does it provide any XOM-specific fundamental update, limiting causal inference.

Relevance 4/10Novelty 4/10Timing: holdings update for Oct. 22, reported on the day of the disclosure

Background

The piece summarizes AVLV’s reported gross activity and specific holdings changes for Oct. 22, highlighting a new XOM stake and small trims elsewhere.

Company-level read

Ticker impact

$AVLVBullishMedium confidence
Context

AVLV reported Oct. 22 holdings changes, adding a new Exxon Mobil stake worth $569.1M and trimming Costco and Caterpillar.

Expected impact

Likely modest support for XOM relative to the ETF’s prior positioning, but limited direct impact on AVLV’s own price.

Evidence & confidence

The article is a holdings-trade disclosure for AVLV, not a fundamental catalyst; it can influence relative flows but not imply immediate repricing.

$XOMBullishMedium confidence
Context

AVLV’s largest buy on Oct. 22 was a new Exxon Mobil position worth $569.1M, at 2.49% of assets.

Expected impact

Mild upward bias for XOM as the market prices incremental institutional/ETF buying, though magnitude is likely limited.

Evidence & confidence

The disclosed buy is large in dollars for the ETF, but it is still one fund’s activity and not a company-specific earnings or guidance event.

$WMTNeutralLow confidence
Context

AVLV added Walmart by $10.3M on Oct. 22, increasing shares by 84,888.

Expected impact

Limited directional impact; any effect would be second-order versus broader market drivers.

Evidence & confidence

The dollar amount is small relative to typical daily market turnover and the article provides no fundamental catalyst.

$NEMNeutralLow confidence
Context

AVLV added Newmont by $6.4M on Oct. 22, increasing shares by 56,376.

Expected impact

Likely negligible near-term price impact; any move would be dominated by gold and equity sentiment.

Evidence & confidence

The article discloses ETF flow size but no new company or commodity catalyst.

$LLYNeutralLow confidence
Context

AVLV added Eli Lilly by $6.4M on Oct. 22, increasing shares by 4,860.

Expected impact

No clear directional impact expected from this single-fund flow disclosure.

Evidence & confidence

The position change is small and not tied to new LLY fundamentals in the article.

$ACNNeutralLow confidence
Context

AVLV added Accenture by $5.2M on Oct. 22, increasing shares by 20,169.

Expected impact

Likely negligible impact on ACN price.

Evidence & confidence

No new ACN-specific information is provided beyond the ETF’s trade.

$COSTNeutralLow confidence
Context

AVLV trimmed Costco by $1.2M on Oct. 22, reducing shares by 1,224.

Expected impact

Slight relative headwind versus peers, but likely too small to move the stock.

Evidence & confidence

The trim is modest and the article lacks any COST-specific negative catalyst.

$CATNeutralLow confidence
Context

AVLV trimmed Caterpillar by $0.6M on Oct. 22, reducing shares by 846.

Expected impact

Negligible impact expected.

Evidence & confidence

Small dollar change and no new CAT fundamentals in the article.

Market effects

Energy and financial-services exposure may see incremental support within value-style ETF flows, given the largest new stake is XOM.

Primarily US large-cap flow signal, with no explicit cross-region catalyst.

Limited global relevance; the story is ETF positioning rather than a global macro or commodity shock.

Counterpoint

ETF holdings changes can be driven by rebalancing mechanics and do not necessarily reflect a new bullish thesis on XOM.

Key entities

  • Avantis U.S. Large Cap Value ETF

    AVLV reported Oct. 22 holdings changes, including a new Exxon Mobil stake and trims to Costco and Caterpillar.

  • Exxon Mobil

    XOM was the largest new position added by AVLV on Oct. 22, worth $569.1M.

Related articles

$LLYMed

Lilly’s retatrutide shows greater efficacy than Ozempic in trial

Eli Lilly (NYSE:LLY) reported that retatrutide outperformed Ozempic in a Phase 3 trial for type 2 diabetes. Retatrutide reduced A1C levels by 2.2% vs. Ozempic's 1.8% and led to 44-47 lbs weight loss vs. Ozempic's 21 lbs. Both doses met primary and secondary endpoints. Common side effects included diarrhea and nausea. Retatrutide is not yet FDA-approved.

$LLYMedAI 8/10

Ozempic led to less weight loss and blood-sugar reduction than Lilly's drug in a diabetes trial.

Eli Lilly's retatrutide showed greater A1C reduction and more than double the weight loss compared to Novo Nordisk's Ozempic in a Phase 3 trial for type 2 diabetes. Participants lost 44-47 lbs on average. Lilly's Kenneth Custer highlighted the potential to shift treatment paradigms. Detailed results will be presented later. Retatrutide is not yet approved.

Med

Walmart Mexico (Walmex) Profit Falls 6.1%

Walmart de México (Walmex) reported a 6.1% drop in Q3 profit to MXN 11,027 million (US$590 million), despite a 3.0% revenue increase. Higher taxes and expenses contributed to the decline, though management expects tax rates to normalize. Walmex reaffirmed its 2026 sales growth guidance of 3.5% to 4.5%.